Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 272.70K | 323.60K | 16.40K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 272.70K | 323.60K | 16.40K | -- | -- |
| Cost of Revenue | 173.50K | 181.10K | 5.70K | -- | -- |
| Gross Profit | 99.10K | 142.50K | 10.70K | -- | -- |
| SG&A Expenses | 112.60K | 201.60K | 52.90K | 100.20K | 119.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 286.30K | 397.20K | 184.30K | 222.40K | 167.40K |
| Operating Income | -13.70K | -73.60K | -167.80K | -222.40K | -167.40K |
| Income Before Tax | -25.10K | -46.60K | -200.10K | -252.00K | -195.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.10K | -46.60K | -200.10K | -252.00K | -195.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.10K | -46.60K | -200.10K | -252.00K | -195.90K |
| EBIT | -13.70K | -73.60K | -167.80K | -222.40K | -167.40K |
| EBITDA | 1.20K | -63.90K | -167.00K | -163.60K | -107.70K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Average Diluted Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |